位于生物医药产业活跃的苏州，苏州大学结合区域优势与自身学科基础，进行了一系列有益探索，通过有组织科研，将实验室发现与产业和临床需求紧密 结合，勾勒出学校在创新药领域"培养人、攻关题、通应用"的实践轨迹。 以跨界融合，夯实创新根基 人才是高校发展的奠基石，更是产业腾飞的原动力。作为教育部批准设立的国内首个专注药学领域的中外合作办学机构，苏州大学国际创新药学院自2024 年招收首批学生以来，始终秉承"推进学科交叉融合"的办学理念，与爱尔兰皇家外科医学院携手，致力于培养既精通科学前沿、又深谙产业逻辑、更具国 际视野的复合型人才。 在生物医药创新这场需要耐心与协作的长跑中，高校如何将学术研究的深厚积淀，有效转化为服务产业发展与临床需求的坚实力量，跑出属于新时代的加 速度？这是一道需要持续探索的实践课题。 目前，研究院聚焦分子靶向药物、生物药、基因和细胞治疗药物、AI药物研发等前沿领域，与行业头部企业达成了在临床前研究、临床试验、人才培养 等多方面的合作。其中，与信达生物开展临床试验项目81个，并成功助力5款创新药上市。今年，双方联合共建的"江苏省创新抗体药物和偶联药物重点实 验室"获得批准建设。这种校企协同的模式将高 ...

本项目由友谊医院牵头完成，原子高科作为本项目创新内容二"核素药物的研发"的核心牵头单位，在神 经母细胞核素药物研发方面做了长期、大量的工作。原子高科成功研制正电子核素药物氟[F]化钠注射 液，完成Ⅲ期临床试验并成功注册上市，填补了国内骨显像正电子核素药物的空白;牵头完成碘[I]化钠 溶液核素团体标准的制定，与友谊医院共同为国产核素药物的标准化生产提供依据;完成正电子核素药 物镓[ Ga]多特安肽注射液的研发和Ⅲ期临床试验，推动了神经母细胞瘤正电子核素药物的研发;成功攻 克碘[I]苄胍注射液制备技术。 原子高科与友谊医院核医学科秉持"产学研医协同创新"理念，构建了长期稳固的战略合作关系。双方在 核素药物供应、科研平台共建、临床试验推进等方面深度联动，合力完成了碘[ I]苄胍制备技术攻关、 氟[F]化钠与镓[Ga]多特安肽临床试验等关键任务，为项目成果落地奠定了坚实基础。今后，原子高科 将持续深耕核医学领域，聚焦重大疾病诊疗需求，加大核素药物研发与技术创新投入，深化与临床机构 的合作，以更优质的产品与服务助力精准医疗发展，为守护人民健康筑起更坚实的屏障。 智通财经APP讯，中国同辐(01763)发布公告，近日，由 ...

Core Viewpoint - The article highlights the strategic transformation of Yunnan Betaini Biotechnology Group Co., Ltd. (Betaini) in response to the changing dynamics of the Chinese cosmetics industry, focusing on long-term value and quality improvement rather than short-term scale growth [1][4][22]. Financial Performance - In the first half of 2025, Betaini achieved operating revenue of 2.372 billion yuan and a net profit attributable to shareholders of 247 million yuan, reflecting resilience amid industry challenges [1]. - The company reported a significant improvement in operating cash flow, reaching 347 million yuan, a year-on-year increase of 145.70%, indicating strong cash flow management [4][6]. - The gross profit margin remained stable, with an overall gross margin of 76.01% in the first half of 2025, showcasing strong profitability and operational efficiency [13]. Strategic Adjustments - Betaini is actively shifting its strategy from pursuing short-term growth to focusing on quality enhancement and structural optimization, which is evident in its reduced reliance on ineffective promotional activities and price competition [4][6]. - The company has optimized its inventory management, improving inventory turnover and focusing on core product categories, laying a solid foundation for future growth [6][11]. Brand and Market Positioning - Betaini has established a clear brand matrix covering various market segments, from high-end anti-aging to mass skincare, with its main brand, Winona, leading the sensitive skin care market in China [7][9]. - The company has successfully activated differentiated market segments, with brands like Aikeman showing a revenue increase of 93.90% year-on-year, indicating strong growth momentum [9]. Research and Development - Betaini has increased its R&D investment, with a research expense ratio of 4.91%, up 0.83 percentage points from the previous year, positioning itself as a leader in the industry [13][14]. - The company has built a comprehensive R&D chain, focusing on basic research and raw material development, which is expected to create a sustainable competitive advantage [14][16]. Operational Strategy - The company is refining its channel strategy, enhancing online marketing efficiency and expanding its offline presence to over 120,000 pharmacies, while also implementing a "BA content" strategy to deepen user engagement [17][18]. - Betaini is expanding its global footprint, particularly in Southeast Asia, focusing on brand building and local adaptation, which is crucial for its international growth [18][20]. Sustainability and ESG Practices - Betaini integrates ESG principles into its operations, achieving high ratings in environmental, social, and governance aspects, which enhances its brand differentiation and aligns with consumer values [20][22]. - The company is building a resilient and sustainable growth model through channel optimization, global expansion, and ESG initiatives, preparing for a potential recovery in performance in the latter half of 2025 [20][22].

Core Viewpoint - The emergence of Beijing Pinchi Medical Equipment Co., Ltd. has significantly reduced the cost of implantable brain stimulators in China, benefiting approximately 3 million Parkinson's disease patients and breaking the foreign monopoly in the neuroregulation field [1][8]. Company Development - Pinchi Medical was established in 2008 and began clinical trials for its brain stimulator in 2009, receiving product registration from the National Medical Products Administration in 2013, making China the second country after the U.S. capable of independently developing and producing brain stimulators [5][6][7][8]. - The company has achieved significant milestones, including the development of key technologies and the production of a brain stimulator that holds over 50% market share in China, benefiting thousands of patients [10][11]. Innovation and Technology - Pinchi Medical has transitioned from imitating foreign products to leading innovation in the neuroregulation sector, focusing on quality and independent research in areas such as rechargeable technology and remote control systems [9][10]. - The company has successfully addressed technical challenges, such as the development of a key component that was previously imported, showcasing its commitment to innovation and self-sufficiency [9][11]. Collaboration and Research - The company emphasizes the importance of collaboration between industry, academia, and healthcare, which has accelerated the commercialization of research outcomes and improved product development [11][12]. - Pinchi Medical has established partnerships with institutions like Tsinghua University and Beijing Tiantan Hospital to enhance its research capabilities and address clinical needs [11][12]. Global Expansion - Pinchi Medical has begun to expand its reach internationally, with its vagus nerve stimulator being implanted in patients in Latin America, marking its first overseas operation [13]. - The company aims to integrate traditional Chinese medical practices with neuroregulation technology to create unique medical solutions, while also navigating the challenges of entering competitive global markets [14].

Group 1 - The 2025 Qingdao Science and Technology Activity Week was officially launched with the theme "Innovation-Driven Development, Technology Leading the Future" [1] - The project team led by Professor Xiao Leyi from Shandong Yanding Holding Group was recognized for their breakthrough achievements in tumor early screening, successfully selected as a leading talent team in Qingdao [1][3] - The evaluation of leading talent teams focused on key areas such as new generation information technology, high-end equipment, and biomedicine, aiming to select core forces that can break through key technologies and promote industrial upgrades [3] Group 2 - Under the strategic layout of Chairman Liu Yuanzhu, Yanding Group has established a talent cultivation system that integrates both introduction and training [5] - The project team has formed a cross-disciplinary innovation consortium by integrating expertise in biomedical engineering, microfluidic technology, and multimodal medical big data [5] - The group has established collaborations with various universities and research institutions, creating multiple research platforms to enhance public health and clinical research capabilities [5] Group 3 - Professor Xiao Leyi has extensive experience in the field of genetics and microfluidic chips, having led four national-level research projects and published 48 papers [7] - The team focuses on the research and industrialization of liquid cell pathology biopsy technology, aiming to develop equipment and reagents with independent intellectual property rights and stable quality [7][8] - The project aims to enhance the early detection rate of tumors, reduce medical expenses for the public, and support the construction of a healthy China and high-quality urban economic development [8] Group 4 - Yanding Group plans to continue deepening its "talent-driven enterprise" strategy through a collaborative innovation model that integrates industry, academia, research, and medicine [10] - The goal is to create a comprehensive industrial chain ecosystem covering tumor early screening, precise diagnosis, and personalized treatment, injecting new technological momentum into the construction of a healthy China [10]

Core Viewpoint - The "magnesium-containing biodegradable polymer bone repair material" developed by the Shenzhen Advanced Institute of Technology has received approval from the National Medical Products Administration, marking a significant advancement in bone defect repair technology and filling a gap in the industry [1][2]. Group 1: Product Development - The product was developed over 15 years by a team led by Qin Ling and Lai Yuxiao at the Translational Medicine Research and Development Center [1]. - The material utilizes a low-temperature 3D printing method, overcoming multiple technical challenges in orthopedic device manufacturing [1]. - The inclusion of magnesium allows the material to achieve mechanical strength comparable to human cancellous bone, providing stable mechanical support during surgical procedures [1]. Group 2: Clinical Trials - A multicenter clinical trial involving 176 patients with bone defects was conducted across eight major research hospitals in China, including Beijing Jishuitan Hospital and Shanghai Sixth People's Hospital [2]. - The results indicated a bone fusion rate exceeding 98% at 24 weeks, with no reported adverse reactions, demonstrating excellent biocompatibility of the material [2]. - Currently, there are no magnesium-related bone repair materials approved for clinical use as medical devices according to public data from the National Medical Products Administration and the U.S. Food and Drug Administration [2].